Clear Street analyst Kaveri Pohlman initiated coverage of Oruka Therapeutics (ORKA) with a Buy rating and $46 price target The firm views the stock’s valuation as “compelling” following the 67% drop year-over-year. Oruka’s “superior assets” are positioned to win market share in psoriasis, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka Therapeutics: Promising Clinical Developments and Strong Financial Health Justify Buy Rating
- Promising Prospects for Oruka Therapeutics: Buy Rating Backed by Strong Growth and Financial Stability
- Oruka Therapeutics Reports Q2 2025 Financial Results
- Oruka Therapeutics: Promising Clinical Developments and Strong Financial Position Justify Buy Rating
- Oruka Therapeutics reports Q2 EPS (46c), consensus (43c)